--- title: Mantle Cell Lymphoma (MCL) url: "https://www.yyhmedical.com/en/guide/blood/mantle-cell-lymphoma" type: MedicalWebPage inLanguage: en-US --- # Mantle Cell Lymphoma (MCL) > Mantle cell lymphoma (MCL) is a relatively uncommon type of mature B-cell non-Hodgkin lymphoma that occurs mainly in older adults. Most patients have disease involving multiple areas of the body at diagnosis, but the course can vary considerably. ## Overview Mantle cell lymphoma (MCL) is a type of non-Hodgkin lymphoma that develops from mature B lymphocytes. MCL is commonly associated with **CCND1 rearrangement and abnormal cyclin D1 expression**, with t(11;14) being the characteristic genetic abnormality. These features play an important role in diagnosis. MCL occurs mainly in older adults and is more common in men. Most patients have disease involving multiple areas at diagnosis. In addition to lymph nodes, MCL may involve the spleen, bone marrow, blood, and gastrointestinal tract. The course of MCL varies considerably. Most patients eventually need systemic treatment, but some people with slowly progressing disease and no significant symptoms can initially be monitored without treatment. ## Causes and Risk Factors The exact cause of MCL is not fully understood. The disease develops through genetic and molecular changes in B lymphocytes. Most cases involve a chromosomal rearrangement affecting **CCND1**, leading to abnormal expression of the cyclin D1 protein and disruption of normal cell-cycle control. MCL is more common in older adults and in men. No specific lifestyle factor has been established as a direct cause, and most patients have no identifiable cause. ## Signs and Symptoms Symptoms of MCL depend on where the lymphoma is located and how extensive the disease is. Some people have no noticeable symptoms at diagnosis, while others are diagnosed after evaluation for enlarged lymph nodes or other abnormalities. Possible signs and symptoms include: - Painless enlarged lymph nodes in the neck, armpits, or groin - An enlarged spleen or liver, which may cause abdominal fullness, discomfort, or feeling full quickly - Bone marrow or blood involvement, which may lead to anemia, low platelet counts, or other blood cell abnormalities - Abdominal pain, diarrhea, or gastrointestinal bleeding if the digestive tract is involved - Fatigue or weakness - B symptoms such as unexplained fever, drenching night sweats, and weight loss Central nervous system involvement is relatively uncommon overall but may be more likely in some patients with high-risk or relapsed disease. ## Diagnosis Diagnosis of MCL usually involves a combination of tissue biopsy, pathology and immunophenotyping, genetic testing, and imaging. After diagnosis, additional tests help determine the extent and biological risk of the disease. **Biopsy** A biopsy of an affected lymph node or other tissue is an important part of diagnosing MCL. When possible, enough tissue is obtained for a complete pathological evaluation. Pathology and immunohistochemistry can identify features associated with MCL, including cyclin D1 and CD5 expression. **Genetic and Molecular Testing** The characteristic genetic abnormality of MCL is t(11;14), involving the **CCND1** gene. Tests such as FISH can help detect this change. Ki-67 can provide information about how rapidly lymphoma cells are dividing, while molecular features such as **TP53 abnormalities** can provide important information about disease risk and treatment planning. Current guidelines recommend TP53 mutation testing at diagnosis. **Blood and Bone Marrow Tests** A complete blood count measures red blood cells, white blood cells, and platelets. In some patients, lymphoma cells may also be found in the blood. Because MCL commonly involves the bone marrow, bone marrow aspiration, biopsy, and flow cytometry may be used to determine whether the marrow is involved. **Imaging** CT can help evaluate lymph nodes and organs throughout the body. PET/CT may provide additional information about disease distribution and staging. For patients who appear to have localized disease, additional evaluation may be needed to rule out hidden involvement of the gastrointestinal tract or bone marrow. ## Treatment Treatment for MCL depends on symptoms, disease stage, biological risk, age, overall health, and previous treatments. Not everyone needs treatment immediately. Some patients with asymptomatic, low-burden, slowly progressing disease can be monitored initially. For patients who need treatment, options now extend beyond traditional immunochemotherapy and may include targeted therapy, maintenance therapy, CAR-T cell therapy, and stem cell transplantation. **Active Monitoring** Some patients with asymptomatic, low-risk, slowly progressing MCL can be monitored without immediate treatment. Treatment may be started if symptoms develop, the lymphoma progresses, blood counts decline, or important organs are affected. **First-Line Systemic Therapy** Treatment commonly includes combinations built around an anti-CD20 monoclonal antibody. The specific regimen depends on age and overall fitness. Younger, medically fit patients may receive more intensive treatment that includes cytarabine, while less intensive approaches may be used for older adults or those who are not candidates for intensive therapy. **BTK inhibitors** are also increasingly being incorporated into MCL treatment and are changing first-line treatment strategies for some patients. **Maintenance Therapy** Some patients who respond to first-line treatment may receive maintenance therapy, such as rituximab, to help prolong remission. **Hematopoietic Stem Cell Transplantation** For selected younger, medically fit patients, **autologous hematopoietic stem cell transplantation (auto-HSCT)** has traditionally been used as consolidation after a response to first-line therapy. As BTK inhibitor–based treatment evolves, the role of autologous transplantation is changing. It is no longer appropriate to assume that every younger patient needs a transplant, and the decision is increasingly individualized. **Relapsed or Refractory MCL** If MCL returns or does not respond adequately to treatment, the next approach depends on previous therapies, duration of response, high-risk features such as TP53 abnormalities, and overall health. Options may include BTK inhibitors and other targeted therapies, CAR-T cell therapy, immunochemotherapy, or clinical trials. **CAR-T Cell Therapy** **Anti-CD19 CAR-T cell therapy** is an important option for selected patients with relapsed or refractory MCL. CAR-T therapy involves collecting a patient's own T cells, modifying them to recognize CD19 on lymphoma cells, and infusing them back into the patient. The timing and suitability of CAR-T therapy depend on previous treatments, disease risk, how quickly the lymphoma is progressing, and overall health. **Allogeneic Hematopoietic Stem Cell Transplantation** With the availability of CAR-T and other newer treatments, allogeneic HSCT is no longer routinely used for most patients with MCL. It may still be considered for selected younger, medically fit patients with relapsed disease when CAR-T therapy is unavailable, has failed, or in other specific circumstances. **Clinical Trials** MCL treatment continues to evolve, including newer BTK inhibitors, BCL-2–directed therapies, CAR-T cell therapy, and other T-cell–redirecting approaches. Clinical trials may be particularly relevant for patients with high-risk, relapsed, or refractory disease. ## Content attribution (YMYL) - Author: - Medically reviewed by: - Last reviewed: - First published: > --- Original (HTML):https://www.yyhmedical.com/en/guide/blood/mantle-cell-lymphoma This is a clean Markdown mirror for large language models; the original page is authoritative.